Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Items 101–200 of 817
Genetics of familial melanoma: 20 years after CDKN 2 A
Aoude, L. G., Wadt, K. A. W., Pritchard, A. L., & Hayward, N. K. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12333 · Cited by 164
“Mutations in CDK4, MITF, BAP1, TERT, POT1, ACD, TERF2IP are rare, with each contributing to 1% of all familial clustering of melanoma.”
BackgroundInfluentialSelf-citationThe genome and epigenome of malignant melanoma
DAHL, C., & GULDBERG, P. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 162
Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 162
Molecular genetics of familial cutaneous melanoma.
Haluska, F. G., & Hodi, F. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.670 · Cited by 154
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
“The CDK4–Rb pathway is disrupted in a majority of melanomas and mechanisms include cyclin D1 amplification (37), activating mutations in CDK4 (29), inactivation of Fbxo4, an E3 ligase that regulates degradation of cyclin D1, and thereby functions as a tumor suppressor (13), and deletion of gene encoding p16Ink4a (8).”
Platz, A., Hansson, J., Mansson-Brahme, E., Lagerlof, B., Linder, S., Ringborg, U., Lundqvist, E., Sevigny, P., & Inganas, M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.697 · Cited by 154
“One potentially interesting candidate gene is the CDK4 gene located at chromosomal locus 12q13, since germline mutations in the CDKN2A-binding domain have recently been described in two melanoma families ( 34 ).”
BackgroundMethodGenetic Epidemiology of Cutaneous Melanoma: A Global Perspective
Goldstein, A. M., & Tucker, M. A. (2001) · Archives of Dermatology · doi:10.1001/archderm.137.11.1493 · Cited by 183
Self-citationWalker, G. J., Flores, J. F., Glendening, J. M., Lin, A. H., Markl, I. D. C., & Fountain, J. W. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2<157::aid-gcc11>3.0.co;2-n · Cited by 161
Self-citationUV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer
Liu-Smith, F., Jia, J., & Zheng, Y. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-56017-5_3 · Cited by 147
“Both of the point mutations impair the CDK4 binding with p16INK4A, thus evading the p16Ink4A inhibitory effect [82].”
BackgroundMalignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S., Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 148
Genetic risk factors for melanoma
Meyle, K. D., & Guldberg, P. (2009) · Human Genetics · doi:10.1007/s00439-009-0715-9 · Cited by 181
“Only 2% of the families in the GenoMEL carried CDK4 mutations (Goldstein et al. 2006), and less than 15 such families have been reported worldwide (Helsing et al. 2008; Molven et al. 2005; Pjanova et al. 2009; SouWr et al. 1998, 2007; Zuo et al. 1996).”
BackgroundPuntervoll, H. E., Yang, X. R., Høberg‐Vetti, H., Bachmann, I. M., Avril, M.-F., Benfodda, M., Catricalà, C., Dalle, S., Duval‐Modeste, A. B., Ghiorzo, P., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101455 · Cited by 178
Self-citationSplicing into Senescence: The Curious Case of p16 and p19ARF
Haber, D. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80441-9 · Cited by 158
“…issue of Cell, melanoma have also been linked to a specific pointKamijo and coworkers (1997) report that much of the mutation in CDK4 (called R24C) (Zuo et al., 1996), whichphenotype ascribed to p16-null mice may in fact be renders the encoded protein insensitive to inhibition byattributed to…”
BackgroundA natural history of melanomas and dysplastic nevi
Tucker, M. A., Fraser, M. C., Goldstein, A. M., Struewing, J. P., King, M. A., Crawford, J. T., Chiazze, E. A., Zametkin, D. P., Fontaine, L. S., & Clark, W. H. (2002) · Cancer · doi:10.1002/cncr.10605 · Cited by 144
Self-citationThe genetics of hereditary melanoma and nevi: 1998 Update
Greene, M. H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11+<2464::aid-cncr3>3.0.co;2-f · Cited by 144
Zou, X., Ray, D., Aziyu, A., Christov, K., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 142
“Melanoma-prone families have been found to carry germline mutations of Cdk4 at the Arg24 residue that render the kinase refractory to Ink4-dependent inhibition (Wolfel et al. 1995; Zuo et al. 1996).”
BackgroundGermline Mutations of the CDKN2 Gene in UK Melanoma Families
Harland, M., Meloni, R., Gruis, N., Pinney, E., Brookes, S., Spurr, N. K., Frischauf, A.-M., Bataille, V., Peters, G., Cuzick, J., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2061 · Cited by 142
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Ibrahim, N., & Haluska, F. G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151541 · Cited by 138
Melanoma: Molecular pathogenesis and emerging target therapies (Review)
Libra (2009) · International Journal of Oncology · doi:10.3892/ijo_00000277 · Cited by 136
Matichard, E., Verpillat, P., Meziani, R., Gérard, B., Descamps, V, Legroux, E., Burnouf, M., Bertrand, G., Bouscarat, F., Archimbaud, A., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.011536 · Cited by 136
Identification, genetic testing, and management of hereditary melanoma
Leachman, S. A., Lucero, O. M., Sampson, J. E., Cassidy, P. B., Bruno, W., Queirolo, P., & Ghiorzo, P. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9661-5 · Cited by 151
Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
Bertolotto, C. (2013) · Scientifica · doi:10.1155/2013/635203 · Cited by 197
“Rare deleterious germinal mutations in the cell cycle regulators CDKN2A and cyclin dependent-kinase 4 (CDK4) have been shown to confer a high cutaneous malignant melanoma risk [35, 36].”
BackgroundTucker, M. A. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.010 · Cited by 131
Self-citationSlominski, A. T., Wortsman, J., Carlson, A. J., Matsuoka, L. Y., Balch, C. M., & Mihm, M. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-1295-mm · Cited by 136
Germline mutation of ARF in a melanoma kindred
Hewitt, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.11.1273 · Cited by 132
“A very small number of additional melanoma families have mutations in the CDK4 gene, which alter the binding of CDK4 to CDKN2A ( 23 ).”
BackgroundDevelopmental Genes and Cancer: Role of Patched in Basal Cell Carcinoma of the Skin
Gailani, M. R., & Bale, A. E. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1103 · Cited by 130
Wachsmuth, R. C., Gaut, R. M., Barrett, J. H., Saunders, C. L., Randerson‐Moor, J. A., Eldridge, A., Martin, N. G., Bishop, D. T., & Newton‐Bishop, J. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01415.x · Cited by 131
“Germline mutations associated with high penetrance have been identi®ed in CDKN2A (Holland et al, 1995; Dracopoli and Fountain, 1996; Harland et al, 1997) and CDK4 (Zuo et al, 1996).”
BackgroundRegulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
AbuHammad, S., Cullinane, C. M., Martin, C., Bacolas, Z., Ward, T. A., Chen, H., Slater, A. A., Ardley, K., Kirby, L., Chan, K. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901323116 · Cited by 138
“PRMT5 is an epigenetic modifier that regulates gene expression through methylating arginine residues on Histones 2A, 3, and 4 (27, 28).”
Epidemiology, Risk Factors, Prevention, and Early Detection of Melanoma
Azoury, S. C., & Lange, J. R. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.07.013 · Cited by 148
Martín, J., Hunt, S. L., Dubus, P., Sotillo, R., Néhmé-Pélluard, F., Magnuson, M. A., Parlow, A. F., Malumbres, M., Ortega, S., & Barbacid, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206506 · Cited by 122
Genotype/Phenotype and Penetrance Studies in Melanoma Families with Germline CDKN2A Mutations
Newton‐Bishop, J., Wachsmuth, R. C., Harland, M., Bataille, V. A., Pinney, E., Mack, P., Baglietto, L., Cuzick, J. M., & Bishop, D. T. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00823.x · Cited by 120
Polsky, D., & Cordon‐Cardo, C. (2003) · Oncogene · doi:10.1038/sj.onc.1206449 · Cited by 140
Localization of a Novel Melanoma Susceptibility Locus to 1p22
Gillanders, E. M., Juo, S. H., Holland, E. A., Jones, M., Nancarrow, D. J., Freas‐Lutz, D., Sood, R. B., Park, N., Faruque, M. U., Markey, C. J., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/377140 · Cited by 117
“The CDKN2A locus (MIM 600160) accounts for susceptibility in ∼25% of all kindreds with familial CMM (Goldstein et al. 2000), whereas mutations in the CDK4 (MIM 123829) gene have, to date, been documented in only three CMM-prone families (Zuo et al. 1996; Soufir et al. 1998).”
BackgroundSelf-citationCutaneous melanoma susceptibility and progression genes
DESNOO, F., & Hayward, N. K. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.033 · Cited by 127
Self-citationHMGIC expression in human adult and fetal tissues and in uterine leiomyomata
Gattás, G. J. F., Quade, B. J., Nowak, R. A., & Morton, C. C. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199908)25:4<384::aid-gcc11>3.0.co;2-d · Cited by 144
Germline mutations predisposing to melanoma
Toussi, A. M., MANS, N. Z., Welborn, J. L., & Kiuru, M. H. (2020) · Journal of Cutaneous Pathology · doi:10.1111/cup.13689 · Cited by 129
“Similar to CDKN2A mutations, CDK4 germline mutations predispose to early onset multiple primary melanomas and increased numbers of atypical nevi.(40,41) CDK4 mutation-associated melanomas”
BackgroundThe Mammalian Cell Cycle: An Overview
Harper, J. V., & Brooks, G. (2004) · Humana Press eBooks · doi:10.1385/1-59259-857-9:113 · Cited by 150
Familial Melanoma: Diagnostic and Management Implications
Rossi, M., Pellegrini, C., Cardelli, L., Ciciarelli, V., Nardo, L. D., & Fargnoli, M. C. (2019) · Dermatology Practical & Conceptual · doi:10.5826/dpc.0901a03 · Cited by 133
Knudson, A. G. (2000) · Annual Review of Genetics · doi:10.1146/annurev.genet.34.1.1 · Cited by 109
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
P16 UV mutations in human skin epithelial tumors
Soufir, N., Molès, J., Vilmer, C., Moch, C., VEROLA, O., Rivet, J., Tesnière, A., Dubertret, L., & Basset‐Séguin, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202915 · Cited by 124
“For mutational analysis of the Cdk4 gene, we screened genomic sequence encompassing residues previously shown to be mutated in familial melanoma (Zuo et al., 1996; Sou®r et al., 1998), or to a ect p16 binding (i.e. domains encompassing the ®rst 58 Nterminal aminoacids or the C-terminal region of…”
MethodBignell, G. R., Barfoot, R., Seal, S., Collins, N., Warren, W., & Stratton, M. R. (1998) · PubMed · Cited by 106
Focus on cutaneous and uveal melanoma specificities
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 118
“R24H) and prevent its interaction with p16 (Zuo et al. 1996).”
BackgroundGenetics of metastasis: melanoma and other cancers
Turner, N., Ware, O. R., & Bosenberg, M. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9893-y · Cited by 110
Chaudru, V., Chompret, A., Bressac-de Paillerets, B., Spatz, A., Avril, M.-F., & Demenais, F. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh136 · Cited by 104
“CDK4 acts as an oncogene, and germline mutations of this gene have been detected in only three melanoma-prone families worldwide (9, 11 ).”
BackgroundMetabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
Lack of Cyclin-Dependent Kinase 4 Inhibits c-myc Tumorigenic Activities in Epithelial Tissues
Miliani de Marval, P. L., Macias, E., Rounbehler, R., Sicinski, P., Kiyokawa, H., Johnson, D. G., Conti, C. J., & Rodriguez-Puebla, M. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7538-7547.2004 · Cited by 101
Novel germline p16 mutation in familial malignant melanoma in southern Sweden.
Borg, Å., Johannsson, U., Jóhannsson, Ó. Þ., Häkansson, S., Westerdahl, J., Måsbäck, A., Olsson, H. L., & Ingvar, C. (1996) · PubMed · Cited by 101
Familial pancreatic cancer: genetic advances
Rustgi, A. K. (2014) · Genes & Development · doi:10.1101/gad.228452.113 · Cited by 101
“Interestingly, CDK4 mutations that occur in the CDKN2-binding domain have been reported in FAMMM kindreds (Zuo et al. 1996).”
BackgroundJannot, A., Meziani, R., Bertrand, G., Gérard, B., Descamps, V., Archimbaud, A., Picard‐Dahan, C., Ollivaud, L., Basset‐Séguin, N., Kérob, D., et al. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201415 · Cited by 112
Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis
Bai, F., Pei, X.-H., Godfrey, V. L., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1269-1277.2003 · Cited by 100
“Finally, missense mutations in the CDK4 locus rendering resistance to INK4 binding have been observed in familial and sporadic melanomas (35, 41).”
BackgroundMolven, A., Grimstvedt, M. B., Steine, S. J., Harland, M., Avril, M., Hayward, N. K., & Akslen, L. A. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20202 · Cited by 101
“Since the initial identification of three melanoma families with a CDK4 mutation (Zuo et al., 1996; Soufir et al., 1998), all CDK4 screening of”
BackgroundMethodInfluentialSelf-citationPopulation-Based Analysis of Prognostic Factors and Survival in Familial Melanoma
Florell, S. R., Boucher, K. M., Garibotti, G., Astle, J. M., Kerber, R. A., Mineau, G. P., Wiggins, C. L., Noyes, R. D., Tsodikov, A. D., Cannon‐Albright, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.999 · Cited by 100
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma
Pho, L., Grossman, D., & Leachman, S. A. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000208791.22442.09 · Cited by 98
Mettus, R. V., & Rane, S. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206888 · Cited by 97
Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma
Zhou, Y., Zhang, X., & Klibanski, A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.006 · Cited by 104
“CDK4 carrying mutations at codon R24 are resistant to the INK4 family of CDK inhibitors and have been identified as germline mutations in familial melanoma patients (Soufir et al., 1998; Zuo et al., 1996).”
BackgroundMolecular genetic basis of pancreatic adenocarcinoma
Hilgers, W., & Kern, S. E. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199909)26:1<1::aid-gcc1>3.0.co;2-x · Cited by 105
Genetic insights into familial cancers – update and recent discoveries
Marsh, D. J., & Zori, R. T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00023-x · Cited by 114
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
Eddy, K., Shah, R., & Chen, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626129 · Cited by 120
CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma
McNeal, A. S., Liu, K., Nakhate, V., Natale, C. A., Duperret, E. K., Capell, B. C., Dentchev, T., Berger, S. L., Herlyn, M., Seykora, J. T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0196 · Cited by 123
“The activating R24C mutation, which occurs in human melanoma (15, 16), rendered CDK4 resistant to p15/ p16 and restored proliferation in both nevus and engineered diBRAFV600E melanocytes (Supplementary Fig.”
Taniai, M., Higuchi, H., Burgart, L. J., & Gores, G. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36021 · Cited by 99
Funk, J. O., Schiller, P. I., Barrett, M. T., Wong, D. J., Kind, P., & Sander, C. A. (1998) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1998.tb01748.x · Cited by 104
Temperature-Sensitive Mutants of p16CDKN2 Associated with Familial Melanoma
Parry, D., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3844 · Cited by 94
“In addition, cyclin D1 expression can be activated by chromosomal translocations (14), and Cdk4 can sustain mutations that reduce its sensitivity to inhibition by p16 (60, 64).”
BackgroundMolecular Biology for the Radiation Oncologist: the 5Rs of Radiobiology meet the Hallmarks of Cancer
Harrington, K. J., Jankowska, P., & Hingorani, M. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.04.009 · Cited by 115
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.
Recio, J. A., Noonan, F. P., Takayama, H., Anver, M. R., Duray, P. H., Rush, W. L., Lindner, G., Fabo, E. C. D., DePinho, R. A., & Merlino, G. T. (2002) · PubMed · Cited by 117
Identification of PTEN mutations in metastatic melanoma specimens
Çelebi, J. T., Shendrik, I., Silvers, D. N., & Peacocke, M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.9.653 · Cited by 103
“regulates cell cycle at the G1 to S transition by inhibiting CDK4 and CDK6. Alterations in CDK4 have also been identified in melanoma, but appear to be rare.”
BackgroundUpdate on familial cancer syndromes and the skin
Tsao, H. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104681 · Cited by 98
Characterization of ligurian melanoma families and risk of occurrence of other neoplasia
Ghiorzo, P., Ciotti, P., Mantelli, M., Heouaine, A., Queirolo, P., Rainero, M. L., Ferrari, C., Santi, P. L., De Marchi, R., Farris, A., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991112)83:4<441::aid-ijc2>3.0.co;2-r · Cited by 88
CDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 91
“One of the best examples is the CDK4R24C mutation that results in insensitivity to INK4 family inhibitors and was first described in patients with familial melanoma [84, 85].”
BackgroundCutaneous melanoma in genetically modified animals
Larue, L., & Beermann, F. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00411.x · Cited by 107
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Marx, S. J., & Simonds, W. F. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0037 · Cited by 92
Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., & Haluska, F. G. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.9.1118 · Cited by 87
The genetics of melanoma: recent advances
Hill, V. K., Gartner, J. J., Samuels, Y., & Goldstein, A. M. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153429 · Cited by 86
Self-citationInsights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma
Perrot, C. Y., Javelaud, D., & Mauviel, A. (2013) · Annals of Dermatology · doi:10.5021/ad.2013.25.2.135 · Cited by 101
Beyond the cell cycle: A new role for Cdk6 in differentiation
Grossel, M. J., & Hinds, P. W. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20712 · Cited by 84
“For instance, cdk4 is specifically mutated in human melanoma [Wolfel et al., 1995; Zuo et al., 1996], while cdk6 activity has been found to be elevated in squamous cell carcinomas [Timmermann et al.”
BackgroundRole of the RB Tumor Suppressor in Cancer
Yamasaki, L. (2006) · Cancer Treatment and Research · doi:10.1007/0-306-48158-8_9 · Cited by 84
Aberrations of the G1- and G1/S-regulating genes in human cancer
Bártková, J., Lukas, J., & Bártek, J. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_16 · Cited by 100
Genetically engineered mouse models of melanoma
Pérez‐Guijarro, E., Day, C., Merlino, G. T., & Zaidi, M. R. (2017) · Cancer · doi:10.1002/cncr.30684 · Cited by 102
“the p16INK4A-CDK4 interaction and constitutive activation of CDK4, was identified in melanomas.(94,95) Homozygous CDK knock-in mice produced”
BackgroundIdentification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma
Bonazzi, V., Irwin, D. L., & Hayward, N. K. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20615 · Cited by 88
“, 2002), whereas mutations in the CDK4 oncogene are rare (Zuo et al., 1996; Soufir et al., 1998; Molven et al., 2005).”
BackgroundSelf-citationGrillo, M., Bott, M. J., Khandke, N., McGinnis, J. P., Miranda, M., Meyyappan, M., Rosfjord, E. C., & Rabindran, S. K. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9066-y · Cited by 89
“CDK4 is amplified in sarcomas and glioblastomas [8] and mutations in CDK4 that render the protein resistant to inhibition by INK4 proteins have been identified in melanomas [40,41].”
BackgroundLogesh, R., Prasad, S. R., Chipurupalli, S., Robinson, N., & Mohankumar, S. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188968 · Cited by 104
The Current Status of Drug Discovery Against the Human Kinome
Eglen, R. M., & Reisine, T. (2009) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2008.164 · Cited by 81
Genetic epidemiology of melanoma
Bataille, V. A. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00313-7 · Cited by 78
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL)
Hatta, Y., & Koeffler, H. (2002) · Leukemia · doi:10.1038/sj.leu.2402458 · Cited by 90
Tsai, K. Y., & Tsao, H. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30037 · Cited by 87
“Consistent with the biochemical importance of this interaction, familial melanoma has also been linked, though rarely, to a particular dominant activating mutation of CDK4 (R24C) that renders it relatively insensitive to p16 inhibition [Wolfel et al., 1995; Zuo et al., 1996; Soufir et al., 1998].”
BackgroundCDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity
Bonelli, P., Tuccillo, F. M., Borrelli, A., Schiattarella, A., & Buonaguro, F. M. (2014) · BioMed Research International · doi:10.1155/2014/361020 · Cited by 82
Nelson, A. A., & Tsao, H. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.005 · Cited by 109
Whole‐exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets
Lyu, J., Song, Z., Chen, J., Shepard, M. J., Song, H., Ren, G., Li, Z., Guo, W., Zhuang, Z., & Shi, Y. (2017) · The Journal of Pathology · doi:10.1002/path.5017 · Cited by 81
Rodríguez‐Puebla, M. L., de Marval, P. L. M., LaCava, M., Moons, D. S., Kiyokawa, H., & Conti, C. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64196-x · Cited by 86
Mantelli, M., Barile, M., Ciotti, P., Ghiorzo, P., Lantieri, F., Pastorino, L., Catricalà, C., Torre, G. D., Folco, U., Grammatico, P., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10135.abs · Cited by 74
Self-citationReddy, M. V. R., Akula, B., Cosenza, S. C., Divakar, S. K. A., Mallireddigari, M. R., Pallela, V. R., Billa, V. K., Subbaiah, D. R. C. V., Bharathi, E. V., Carpio, R. V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401073p · Cited by 80
A mutation hotspot at the p14ARF splice site
Harland, M., Taylor, C., Chambers, P. A., Kukalizch, K., Randerson‐Moor, J. A., Gruis, N. A., de Snoo, F. A., ter Huurne, J., Goldstein, A. M., Tucker, M. A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208678 · Cited by 85
Self-citationWikman, H., & Kettunen, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.4.515 · Cited by 72
Mutation screening of theCDKN2A promoter in melanoma families
Harland, M., Holland, E. A., Ghiorzo, P., Mantelli, M., Bianchi-Scarr�, G., Goldstein, A. M., Tucker, M. A., Ponder, B. A. J., Mann, G. J., Bishop, D. T., et al. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200005)28:1<45::aid-gcc6>3.0.co;2-f · Cited by 73
Self-citationSchmidt, B., Rose, A., Steinhoff, C., Strohmeyer, T. G., Hartmann, M., & Ackermann, R. (2001) · PubMed · Cited by 81
Contribution of Germline Mutations in BRCA2 , P16 INK4A , P14 ARF and P15 to Uveal Melanoma
Hearle, N., Damato, B. E., Humphreys, J., Wixey, J., Green, H. E., Stone, J. G., Easton, D. F., & Houlston, R. S. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0026 · Cited by 72
Clinic-based study of plexiform neurofibromas in neurofibromatosis 1
Waggoner, D. J., Towbin, J., Gottesman, G., & Gutmann, D. H. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000515)92:2<132::aid-ajmg10>3.0.co;2-6 · Cited by 130
Serological evidence of an association betweenChlamydia pneumoniae infection and lung cancer
Laurila, A. L., Anttila, T., Läärä, E., Bloigu, A., Virtamo, J., Albanes, D., Leinonen, M., & Saikku, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1<31::aid-ijc6>3.0.co;2-1 · Cited by 138
Pathways to Melanoma Development: Lessons from the Mouse
Walker, G. J., & Hayward, N. K. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00217.x · Cited by 83
Self-citationCDKN2a/p16INK4a Mutations and Lack of p19ARF Involvement in Familial Melanoma Kindreds
Fargnoli, M. C., Chimenti, S., Peris, K., Keller, G., Soyer, H. P., Pozzo, V. D., & Höfler, H. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00412.x · Cited by 80
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.